I. Gore

发表

A Randomized Phase II Trial of Vismodegib versus Placebo with FOLFOX or FOLFIRI and Bevacizumab in Patients with Previously Untreated Metastatic Colorectal Cancer

J. Berlin, M. Mulcahy, L. Hart, 2012, Clinical Cancer Research.

Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer.

L. Saltz, A. Venook, L. Fong, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

PSMA ADC monotherapy in patients with progressive metastatic castration‐resistant prostate cancer following abiraterone and/or enzalutamide: Efficacy and safety in open‐label single‐arm phase 2 study

David C. Smith, B. Somer, N. Stambler, 2019, The Prostate.

A phase 2 study of a fixed combination of uracil and ftorafur and leucovorin given orally in a twice‐daily regimen to treat patients with recurrent metastatic breast cancer

G. Hortobagyi, N. Ibrahim, J. Murray, 2010, Cancer.

CheckMate 384: Phase IIIb/IV trial of nivolumab (nivo) 480 mg Q4W versus 240 mg Q2W after ≤ 12 months of nivo in previously treated advanced NSCLC.

N. Reinmuth, K. O'Byrne, S. Rabindran, 2019, Journal of Clinical Oncology.

Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

M. Buyse, N. Robert, M. Gnant, 2016, The Lancet. Oncology.

Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR

Gayatry Mohapatra, D. Haber, Sreenath V. Sharma, 2005, Nature Genetics.

Long‐term safety and survival with gefitinib in select patients with advanced non–small cell lung cancer: Results from the US IRESSA Clinical Access Program (ICAP)

L. Sequist, F. Hirsch, P. Bunn, 2018, Cancer.

Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 study.

N. Robert, F. Holmes, J. O’Shaughnessy, 2013, The Lancet. Oncology.

Safety analysis of a randomized phase II trial of hedgehog pathway inhibitor (HPI) GDC-0449 versus placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreated metastatic colorectal cancer (mCRC).

J. Berlin, L. Hart, R. Hermann, 2010 .

A phase II study of the anti-CTLA4 monoclonal antibody (mAb), CP-675,206, in patients with refractory metastatic adenocarcinoma of the colon or rectum

L. Saltz, A. Venook, L. Fong, 2007 .

Abstract CT128: Effects of adding budesonide or colestipol to loperamide prophylaxis on neratinib-associated diarrhea in patients (pts) with HER2+ early-stage breast cancer (eBC): the CONTROL trial

D. Tripathy, N. Iannotti, C. Barcenas, 2017 .

A comparison of efficacy of sargramostim (yeast-derived RhuGM-CSF) and filgrastim (bacteria-derived RhuG-CSF) in the therapeutic setting of chemotherapy-induced myelosuppression.

N. Robert, R. Beveridge, W. Taylor, 1998, Cancer investigation.

Identification of Histopathologic Risk Groups in Stage IB Squamous Cell Carcinoma of the Cervix

K. Hatch, S. Soong, H. Shingleton, 1985, Obstetrics and gynecology.

Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial.

M. Buyse, M. Gnant, H. Iwata, 2023, European journal of cancer.

A planned comparison of menopausal symptoms during year 1 in patients receiving either exemestane or tamoxifen in a double-blind adjuvant hormonal study

J. Pippen, S. Jones, J. Blum, 2003 .

Randomized Phase II Trial of Parsatuzumab (Anti‐EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First‐Line Metastatic Colorectal Cancer

P. Hegde, E. Van Cutsem, H. Hurwitz, 2017, The oncologist.

Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer.

P. Hegde, E. Van Cutsem, H. Hurwitz, 2017, The oncologist.

A phase 2 study of prostate specific membrane antigen antibody drug conjugate (PSMA ADC) in patients (pts) with progressive metastatic castration-resistant prostate cancer (mCRPC) following abiraterone and/or enzalutamide (abi/enz).

David C. Smith, B. Somer, N. Stambler, 2015 .

Randomized Phase II Trial of Parsatuzumab (Anti‐EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First‐Line Metastatic Colorectal Cancer

P. Hegde, E. Van Cutsem, H. Hurwitz, 2017, The oncologist.

Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: diarrheal toxicity in the CONTROL trial.

R. Bose, H. Rugo, D. Tripathy, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.